



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY

**Assessment of Doppler haemodynamic changes
suggestive of portal hypertension in cirrhotic
HCV patients after sustained virological
response to direct antiviral agents**

Thesis

Submitted for Partial Fulfillment of Master Degree
In Tropical Medicine

By

Mennatullah Medhat Ezzat
(M.B.,B.Ch.)

Supervised by

Prof. Dr. Sara Mahmoud Abdelhakam

Professor of Tropical Medicine
Faculty of Medicine - Ain Shams University

Dr. Amira Mahmoud Al-Balakosy

Lecturer of Tropical Medicine
Faculty of Medicine - Ain Shams University

Dr. Ahmed Abdullah Ghalwash

Consultant of Hepatology and Gastroenterology
Agouza Police Hospital

Faculty of Medicine
Ain Shams University

2021

Acknowledgement

First and foremost I am deeply thankful to ALLAH the most merciful and the Most Kind

I am extremely grateful to **Prof. Dr. Sara Mahmoud Abdelhakam, Professor of Tropical Medicine, Faculty of Medicine - Ain Shams University**, for supportive advice, great guidance for working under her supervision, precious teaching and the continuous education extended to me beyond the limits of this thesis.

Words could not express the feeling of respect and appreciation to **Dr. Amira Mahmoud Al-Balakosy, Lecturer of Tropical Medicine, Faculty of Medicine - Ain Shams University** for her Infinite guidance and support, priceless supervision, valuable guidance and the time and effort she generously gave to me.

Also, my deep thanks to **Dr. Ahmed Abdullah Ghalwash, Consultant of Hepatology and Gastroenterology, Agouza Police Hospital**, for his great help, guidance and scientific supervision during this work.

It is my honor to express my deep gratefulness to my professors, my colleagues and each member in the Tropical Medicine department.

Mennatullah Medhat

List of Contents

Title	Page
▪ List of Abbreviations	I
▪ List of Tables	IV
▪ List of Figures	VII
▪ Introduction	1
▪ Aim of the Work	4
▪ Review of Literature	
- Chapter (1): HCV Infection	5
- Chapter (2): HCV Treatment.....	24
- Chapter (3): Duplex Ultrasonography in Portal Hypertension	80
▪ Patients and Methods	118
▪ Results	127
▪ Discussion	144
▪ Summary	156
▪ Conclusion	159
▪ Recommendations	160
▪ References	162
▪ Arabic Summary	--

List of Abbreviations

2'5'OAS	2'5'-Oligoadenylate Synthetase
AFP	Alpha Feto Protein
ALT	Alanine Aminotransferase
AST	Aspartate Aminotransferase
BMI	Body Mass Index
Cag	Core Antigen
CDC	Centers for Disease Control and Prevention
CHC	Chronic Hepatitis C
CI	Portal Vein Congestive Index
CLD	Chronic Liver Disease
CRP	C Reactive Protein
CSA	Cross Sectional Area
CYP	Cytochrome P450
DAAs	Direct Antiviral Agents
DNA	Deoxyribnucleic Acid
E proteins	Envelope glycoproteins
EASL	European association for the Study of the Liver
eGFR	Estimated Glomerular Filtration Rate
EIA	Enzyme Immunoassay
ER	Endoplasmic Reticulum
ESRD	End Stage Renal Disease
ETR	End of Treatment Response
EV	Esophageal Varices
EVR	Early Virologic Response
g/l	Gram per Litre
GB	Gall Bladder

List of Abbreviations

GE/mL	Genome Equivalents per Milliliter
HARI	Hepatic Artery Resistance Index
HAV	Hepatitis A Virus
HBsAg	Hepatitis B Surface Antigen
HBV	Hepatitis B Virus
HCC	Hepatocellular Carcinoma
HCV Ab	Hepatitis C Virus Antibody
HCV RNA	Hepatitis C Virus Ribonucleic Acid
HCV	Hepatitis C Virus
HIV	Human Immunodeficiency Virus
HVR	Hypervariable Regions
INR	International Normalized Ratio
IRES	Internal ribosome entry site
ISGF3	IFN-Stimulated Gene Factor 3
ISGs	IFN-Stimulated Genes
IVC	Inferior Vena Cava
Jak/STAT	Janus Kinase/Signal Transducers and Activators of Transcription
LDL	low Density Lipoprotein
LDLR	Low Density Lipoprotein Receptor
LFTs	Liver Function Tests
LGV	Left Gastric Vein
MC	Mixed Cryoglobulinemia
MHV	Main Hepatic Vein
mmol/l	Millimoles per Litre
MPV	Main Portal Vein

List of Abbreviations

NCCVH	National Committee for Control of Viral Hepatitis
NPIs	Nucleoside Polymerase Inhibitors
NPV	Negative Predictive Value
PBMCs	Peripheral Blood Mononuclear Cells
PCR	Polymerase Chain Reaction
Peg IFN	Pegylated Interferon
P-gp	P-glycoprotein
PHA	Proper Hepatic Artery
PI	Pulsatility Index
PIs	Protease Inhibitors
PPV	Positive Predictive Value
PT	Prothrombin Time
PTT	Partial Thromboplastin Time
PUV	Paraumbilical Vein
PV	Portal Vein
PVV	Portal Vein Velocity
PWIDs	People Who Inject Drugs
RBV	Ribavirin
RdRp	RNA Dependent RNA Polymerase
RI	Resistive Index
RT-PCR	Real-Time Polymerase Chain Reaction
RVR	Rapid Virological Response
SD	Standard Deviation
SHEA	Society for Healthcare Epidemiology of America
SR-B1	Scavenger Receptor Class B Type 1

List of Abbreviations

SVR	Sustained Virologic Response
Th1	T Helper 1 Cells
TIPS	Transjugular Intrahepatic Portosystemic Shunt
TMA	Transcription-Mediated Amplification
TMDs	Two Transmembrane Domains
WHO	World Health Organization

List of Tables

Table No.	Title	Page
Table (1):	Recommended Treatment for Chronic Hepatitis C Virus Infection by the Most Common Genotypes in the United States	30
Table (2):	Predictors of SVR	32
Table (3):	Side effects of Pegylated Interferon and Ribavirin for the therapy of HCV Infection.....	32
Table (4):	Absolute and relative contraindications to Interferon and ribavirin	34
Table (5):	Approved HCV DAAs in Europe in 2018	35
Table (6):	Drug-drug interactions between HCV DAAs and antiretrovirals	41
Table (7):	Drug-drug interactions between HCV DAAs and illicit recreational drugs or drugs of abuse	42
Table (8):	Drug-drug interactions between HCV DAAs and lipid lowering drugs.....	43
Table (9):	Drug-drug interactions between HCV DAAs and Immunosuppressants	43
Table (10):	Drug-drug interactions between HCV DAAs and CNS drugs	44

List of Tables (Continued)

Table No.	Title	Page
Table (11):	Drug-drug interactions between HCV DAAs and cardiovascular drugs.....	45
Table (12):	Age, sex distribution of studied patients and other chronic diseases.....	127
Table (13):	Clinical data of enrolled patients of the study (n=50).....	128
Table (14):	Comparison between laboratory results of enrolled patients before and after treatment	129
Table (15):	FIB4 values before and 6 months after treatment among studied patients.....	132
Table (16):	Ultrasonographic findings among the studied patients before treatment and 6 months after treatment.....	133
Table (17):	Comparison between amount of ascites before and after the treatment....	134
Table (18):	Doppler ultrasonographic findings (measurements) in the enrolled patients before treatment and 6 months after treatment	135
Table (19):	Portosystemic collaterals before and after treatment among the studied patients.....	139

List of Tables (Continued)

Table No.	Title	Page
Table (20):	Upper GIT endoscopic findings among enrolled patients before and 6 months after treatment	139
Table (21):	Liver stiffness measurement (KPa) by fibroscan before treatment and 6 months after treatment among the studied patients	141
Table (22):	Correlation between liver stiffness measurements by fibroscan and cross sectional area of portal vein, hepatic artery resistance index, splenic artery resistance index and portal hypertensive index	142
Table (23):	correlation between liver stiffness measurements by fibroscan and cross sectional area of portal vein, hepatic artery resistance index, splenic artery resistance index and portal hypertensive index	143

List of Figures

Figure No.	Title	Page
Fig. (1):	Genome organisation of Hepatitis C virus	37
Fig. (2):	Model of the HCV lifecycle	39
Fig. (3):	Mechanism of action of DAAs	39
Fig. (4):	A 35 year old female with steatosis	85
Fig. (5):	A 79 year old male with right heart failure	85
Fig. (6):	A 43-year-old female with hepatitis C cirrhosis.....	88
Fig. (7):	A 47-year-old male with hepatitis C cirrhosis.....	89
Fig. (8):	A 39-year-old male with hepatitis B cirrhosis.....	89
Fig. (9):	A 44-year-old male with alcoholic cirrhosis.....	90
Fig. (10):	A 38-year-old female with liver transplant	92
Fig. (11):	A 52-year-old male with alcoholic cirrhosis.....	93
Fig. (12):	A 47-year-old male with hepatitis C cirrhosis.....	95
Fig. (13):	A 39-year-old male with hepatitis B cirrhosis.....	96
Fig. (14):	A 44-year-old male with alcoholic cirrhosis.....	96

List of Figures (Continued)

Figure No.	Title	Page
Fig. (15):	Anatomy of the hepatic veins	101
Fig. (16):	A 33-year-old male with hepatitis C.....	103
Fig. (17):	A 44-year-old male with hepatitis C cirrhosis.....	104
Fig. (18):	A 53-year-old male with alcoholic cirrhosis.....	107
Fig. (19):	Major portosystemic collaterals.....	114
Fig. (20):	Demonstration of studied patients according to their gender.....	127
Fig. (21):	Demonstration of the decrease in AST level before treatment and 6 months after the treatment	130
Fig. (22):	Demonstration of the decrease in ALT level before treatment and 6 months after the treatment	130
Fig. (23):	Demonstration of the increase in level of Albumin level before treatment and 6 months after the treatment	131
Fig. (24):	Shows statistically significant change in FIB4 value in the enrolled patients before and after the treatment.....	132
Fig. (25):	Demonstration of patients included in the study who had ascites before and after tt.....	134
Fig. (26):	Shows statistically significant difference (decrease) in portal vein cross sectional area before and after 6 months of the treatment with P-value 0.001*	136